Literature DB >> 21972236

Pleiotropic opioid regulation of spinal endomorphin 2 release and its adaptations to opioid withdrawal are sexually dimorphic.

Sumita Chakrabarti1, Nai-Jiang Liu, James E Zadina, Tarak Sharma, Alan R Gintzler.   

Abstract

We studied adaptations to acute precipitated opioid withdrawal of spinal μ-opioid receptor (MOR)-coupled regulation of the release of endomorphin 2 (EM2). The release of this highly MOR-selective endogenous opioid from opioid-naive spinal tissue of male rats is subjected to MOR-coupled positive as well as negative modulation via cholera toxin-sensitive G(s) and pertussis toxin-sensitive G(i)/G(o), respectively. The net effect of this concomitant bidirectional modulation is inhibitory. MOR-coupled pleiotropic regulation of EM2 release is retained in opioid-withdrawn spinal tissue of male rats, but the balance of MOR-coupled inhibitory and facilitatory regulation shifted such that facilitatory regulation predominates. Augmented coupling of MOR to G(s) is causally associated with this change. Strikingly, pleiotropic characteristics of MOR-coupled regulation of spinal EM2 release and adaptations thereof to opioid withdrawal are male-specific. In females, MOR-coupled regulation of EM2 release from opioid-naive and -withdrawn spinal tissue does not have a significant G(s)-coupled facilitatory component, and MOR-coupled inhibition of EM2 release persists unabated in withdrawn preparations. The male-specific adaptations to chronic morphine that shift the relative predominance of opposing dual G protein-coupled MOR pathways provides a mechanism for mitigating inhibitory MOR signaling without losing MOR-coupled feedback regulation. These adaptations enable using endogenous EM2 as a substitute for morphine that had been precipitously removed. The sexually dimorphic functionality and regulation of spinal EM2/MOR-coupled signaling suggest the clinical utility of using sex-specific treatments for addiction that harness the activity of endogenous opioids.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21972236      PMCID: PMC3270060          DOI: 10.1124/jpet.111.186874

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

1.  Regulation of spinal dynorphin 1-17 release by endogenous pituitary adenylyl cyclase-activating polypeptide in the male rat: relevance of excitation via disinhibition.

Authors:  Nai-Jiang Liu; Stephen A Schnell; Stefan Schulz; Martin W Wessendorf; Alan R Gintzler
Journal:  J Pharmacol Exp Ther       Date:  2010-10-25       Impact factor: 4.030

2.  Downregulation of mu-opioid receptor mRNA in the mediobasal hypothalamus of the female guinea pig following morphine treatment.

Authors:  O K Rønnekleiv; M A Bosch; M J Cunningham; E J Wagner; D K Grandy; M J Kelly
Journal:  Neurosci Lett       Date:  1996-09-27       Impact factor: 3.046

3.  Differential effect of chronic morphine on mRNA encoding adenylyl cyclase isoforms: relevance to physiological sequela of tolerance/dependence.

Authors:  M Rivera; A R Gintzler
Journal:  Brain Res Mol Brain Res       Date:  1998-02

4.  Gender-related differences in the antinociceptive properties of morphine.

Authors:  T J Cicero; B Nock; E R Meyer
Journal:  J Pharmacol Exp Ther       Date:  1996-11       Impact factor: 4.030

5.  A potent and selective endogenous agonist for the mu-opiate receptor.

Authors:  J E Zadina; L Hackler; L J Ge; A J Kastin
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

6.  Sex-related differences in morphine's antinociceptive activity: relationship to serum and brain morphine concentrations.

Authors:  T J Cicero; B Nock; E R Meyer
Journal:  J Pharmacol Exp Ther       Date:  1997-08       Impact factor: 4.030

7.  Localization of endomorphin-2-like immunoreactivity in the rat medulla and spinal cord.

Authors:  S Martin-Schild; J E Zadina; A A Gerall; S Vigh; A J Kastin
Journal:  Peptides       Date:  1997       Impact factor: 3.750

8.  Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain.

Authors:  L J Sim; D E Selley; S I Dworkin; S R Childers
Journal:  J Neurosci       Date:  1996-04-15       Impact factor: 6.167

9.  Proopiomelanocortin (POMC) mRNA expression: distribution and region-specific down-regulation by chronic morphine in female guinea pig hypothalamus.

Authors:  Y Fang; M J Kelly; O K Rønnekleiv
Journal:  Brain Res Mol Brain Res       Date:  1998-03-30

10.  Long-term exposure to opioid antagonists up-regulates prodynorphin gene expression in rat brain.

Authors:  P Romualdi; G Lesa; A Donatini; S Ferri
Journal:  Brain Res       Date:  1995-02-20       Impact factor: 3.252

View more
  11 in total

1.  Examining the factor structure of the Clinical Opiate Withdrawal Scale: A secondary data analysis from the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003.

Authors:  Celestina Barbosa-Leiker; Sterling McPherson; Mary Rose Mamey; G Leonard Burns; Matthew E Layton; John Roll; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2015-04-11       Impact factor: 4.492

2.  Mu-opioid receptor splice variants: sex-dependent regulation by chronic morphine.

Authors:  Vittorio Verzillo; Priyanka A Madia; Nai-Jiang Liu; Sumita Chakrabarti; Alan R Gintzler
Journal:  J Neurochem       Date:  2014-06-11       Impact factor: 5.372

3.  Phosphorylation of unique C-terminal sites of the mu-opioid receptor variants 1B2 and 1C1 influences their Gs association following chronic morphine.

Authors:  Sumita Chakrabarti; Nai-Jiang Liu; Alan R Gintzler
Journal:  J Neurochem       Date:  2019-10-20       Impact factor: 5.372

4.  Chronic opioid treatment augments caveolin-1 scaffolding: relevance to stimulatory μ-opioid receptor adenylyl cyclase signaling.

Authors:  Sumita Chakrabarti; Andrew Chang; Nai-Jiang Liu; Alan R Gintzler
Journal:  J Neurochem       Date:  2016-10-18       Impact factor: 5.372

5.  Contribution of Endogenous Spinal Endomorphin 2 to Intrathecal Opioid Antinociception in Rats Is Agonist Dependent and Sexually Dimorphic.

Authors:  Arjun Kumar; Nai-Jiang Liu; Priyanka A Madia; Alan R Gintzler
Journal:  J Pain       Date:  2015-09-02       Impact factor: 5.820

Review 6.  Sex-specific cell signaling: the corticotropin-releasing factor receptor model.

Authors:  Rita J Valentino; Elisabeth Van Bockstaele; Debra Bangasser
Journal:  Trends Pharmacol Sci       Date:  2013-07-11       Impact factor: 14.819

7.  On the g-protein-coupled receptor heteromers and their allosteric receptor-receptor interactions in the central nervous system: focus on their role in pain modulation.

Authors:  Dasiel O Borroto-Escuela; Wilber Romero-Fernandez; Alicia Rivera; Kathleen Van Craenenbroeck; Alexander O Tarakanov; Luigi F Agnati; Kjell Fuxe
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-17       Impact factor: 2.629

8.  Sex differences in the neural mechanisms mediating addiction: a new synthesis and hypothesis.

Authors:  Jill B Becker; Adam N Perry; Christel Westenbroek
Journal:  Biol Sex Differ       Date:  2012-06-07       Impact factor: 5.027

9.  Sex-specific mechanisms of tolerance for the cannabinoid agonists CP55,940 and delta-9-tetrahydrocannabinol (Δ9-THC).

Authors:  Angela N Henderson-Redmond; Diana E Sepulveda; Erin L Ferguson; Aaron M Kline; Mary K Piscura; Daniel J Morgan
Journal:  Psychopharmacology (Berl)       Date:  2021-06-24       Impact factor: 4.415

10.  Sex and gender disparity in pathology, disability, referral pattern, and wait time for surgery in workers with shoulder injury.

Authors:  Helen Razmjou; Sandra Lincoln; Iona Macritchie; Robin R Richards; Danielle Medeiros; Amr Elmaraghy
Journal:  BMC Musculoskelet Disord       Date:  2016-09-21       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.